within Pharmacolibrary.Drugs.ATC.L;

model L01EB05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0002916666666666667,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.276,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.684,
    k12             = 49.8,
    k21             = 49.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rociletinib is an oral, small molecule, irreversible inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), developed for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutation. It showed clinical promise in early trials but has since been discontinued and is not approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced non-small cell lung cancer (NSCLC), as reported in phase I/II clinical studies.</p><h4>References</h4><ol><li><p>Ballard, P, et al., &amp; Cross, D (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 22(20) 5130–5140. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-16-0399\">10.1158/1078-0432.CCR-16-0399</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27435396/\">https://pubmed.ncbi.nlm.nih.gov/27435396</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EB05;
